Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?

Recent randomized phase III trials (KEYNOTE-407 and IMpower131) reported that adding anti-programmed death (ligand) 1 (anti-PD-(L)1) antibodies in combination with taxane-platinum improve the therapeutic efficacy for advanced squamous non-small-cell lung cancer (NSCLC). However, there is no head-to-...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yaxiong, Zhou, Huaqiang, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276157/
https://www.ncbi.nlm.nih.gov/pubmed/30509312
http://dx.doi.org/10.1186/s40425-018-0427-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276157/
https://www.ncbi.nlm.nih.gov/pubmed/30509312
http://dx.doi.org/10.1186/s40425-018-0427-6

Ejemplares similares